title: Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice.
abstract: In research towards the development of new atypical antipsychotic agents, one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system. The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine (7) is described. Compound 7e, 5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy dro-1H- indol-2-one, from this series showed significant affinities at the 5-HT1A and 5-HT2A receptors and moderate affinity at the D2 receptor. 7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature.
authors.affiliation: Department of Pharmacy, Birla Institute of Technology and Science, Rajasthan, India.
authors.forename: P
authors.initials: P
authors.lastname: Srinivas
authors.forename: A R
authors.initials: AR
authors.lastname: Subramanian
authors.forename: P
authors.initials: P
authors.lastname: Brust
authors.forename: S A
authors.initials: SA
authors.lastname: Raghavan
authors.forename: J B
authors.initials: JB
authors.lastname: Rangisetty
authors.forename: C N
authors.initials: CN
authors.lastname: Gupta
authors.forename: N
authors.initials: N
authors.lastname: Sridhar
authors.forename: A
authors.initials: A
authors.lastname: Veeranjaneyulu
authors.forename: P
authors.initials: P
authors.lastname: Parimoo
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000037:antagonists & inhibitors / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D001058:Apomorphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001667:Binding, Competitive / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced / Q000517:prevention & control; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000493:pharmacokinetics; D006220:Haloperidol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D051379:Mice; D009281:Naphthalenes / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D010879:Piperazines / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D044263:Receptors, Serotonin, 5-HT1; D013134:Spiperone / Q000493:pharmacokinetics; D013239:Stereotyped Behavior / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D009281:Naphthalenes; D010879:Piperazines; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D013134:Spiperone; D006220:Haloperidol; D001058:Apomorphine